Portal de Periódicos da CAPES

AB1231 Efficacy and cost analysis of a systematic switch from originator infliximab to biossimilar ct-p13 of all patients with inflammatory arthritis from a single centre

2018; BMJ; Linguagem: Inglês

10.1136/annrheumdis-2018-eular.5844

1468-2060

Ana Valido, Joana Silva-Dinis, María José Saavedra, Noemia Liege Maria da Cunha Bernardo, João Eurico Fonseca,

Pharmaceutical studies and practices

Objectives The aim of this study was to analyse efficacy, safety and cost savings of switching from infliximab originator (IFXor) to the biosimilar (BS) CT-P13 in single centre. Methods Eligible patients were those older than 18 years old with the diagnosis of rheumatoid arthritis (RA), spondylarthritis (SpA) and psoriatic arthritis (PsA) on treatment (Tx) with IFXor for at least 6 months and with stable disease activity. In December 2016 all eligible patients were proposed to switch to CT-P13. At the day of the last Tx with IFXor, informed consent, data and blood samples were collected. On the next Tx day, CT-P13 was administered after standard evaluation of efficacy and safety. Efficacy was measured considering change from baseline in Disease Activity Score in 28 joints (DAS28) for RA and PsA and in Ankylosing Spondylitis Disease Activity Score (ASDAS) for SpA. Disease worsening was considered when an increase of 1.2 from baseline in DAS28 or an increase of 1.1 in ASDAS occurred. A cost analysis was done based on the purchasing prices of the 2 drugs at our centre. Results In a 12 months period switch to CT-P13 was performed in 60 patients for non-medical reasons. Disease activity (DA) was stable over the observation period and similar to the values observed with IFXor. Median follow-up time was 261 days during which disease worsening occurred in 3 (5%) patients. 1 patient had a minor adverse event (oedema of the lip). These 4 (6.7%) patients stopped the BS. One returned to IFXor and the other 3 switched to another drug. The switch to CT-P13 represented a 26.4% reduction of costs in the use of IFX Tx in these patients. Conclusions The switch in routine care of a group of RA, SpA and PsA patients from IFXor to CT-P13 did not affect efficacy and safety and reduced costs in 26.4%. Reference [1 ] Bente Glintborg, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry . Ann Rheum Dis 2017 ;0:1–6. Disclosure of Interest None declared